Recent Price Movement and Market Context
On 16 Mar 2026, Windlas Biotech’s stock price touched an intraday low of Rs.699.35, representing a 3.77% drop for the day and a 2.86% decline overall. This marks the lowest price level for the stock in the past year, down from its 52-week high of Rs.1,137.60. The stock has been on a downward trajectory for four consecutive trading sessions, losing 6.61% over this period. It has underperformed its sector by 1.37% on the day, reflecting a broader weakness in the Pharmaceuticals & Biotechnology segment.
Market conditions have also been challenging. The Sensex opened lower at 74,415.79, down 0.2%, and is currently trading near 74,562.41. The benchmark index is 4.21% above its own 52-week low of 71,425.01 and has experienced an 8.27% decline over the past three weeks. The Sensex is trading below its 50-day moving average, which itself is below the 200-day moving average, signalling a bearish trend. Windlas Biotech’s share price is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — underscoring the prevailing negative momentum.
Financial Performance and Valuation Metrics
Windlas Biotech’s financial results have contributed to the subdued market sentiment. The company reported a quarterly profit after tax (PAT) of Rs.15.00 crores, which is down 10.9% compared to the average of the previous four quarters. Its quarterly PBDIT (Profit Before Depreciation, Interest and Taxes) also hit a low of Rs.24.38 crores. Cash and cash equivalents stood at Rs.15.03 crores for the half-year period, marking the lowest level recorded recently.
Over the last five years, the company’s operating profit has grown at an annualised rate of 18.82%, which is modest relative to sector peers. Despite this, the stock has underperformed the broader market significantly. While the BSE500 index generated returns of 4.98% over the past year, Windlas Biotech’s stock declined by 20.28%. This divergence highlights challenges in translating profit growth into shareholder returns.
This week's revealed pick, a Large Cap from Public Banks with TARGET PRICE, is already showing movement! Get the complete analysis before it's too late.
- - Target price included
- - Early movement detected
- - Complete analysis ready
Valuation and Shareholding Structure
The company maintains a low average debt-to-equity ratio of zero, indicating a debt-free capital structure. Its return on equity (ROE) stands at 12.6%, suggesting a fair level of profitability relative to shareholder funds. The stock trades at a price-to-book value of 2.9, which is a premium compared to the historical valuations of its peers in the Pharmaceuticals & Biotechnology sector. The price-earnings-to-growth (PEG) ratio is 3.2, reflecting the relationship between its price-to-earnings ratio and earnings growth rate.
Promoters remain the majority shareholders, maintaining control over the company’s strategic direction. This ownership concentration is typical for small-cap companies in the sector.
Technical Indicators and Market Sentiment
Technical analysis reveals a predominantly bearish outlook for Windlas Biotech. The Moving Average Convergence Divergence (MACD) indicator is bearish on a weekly basis and mildly bearish monthly. Bollinger Bands also signal bearish trends on both weekly and monthly charts. The daily moving averages confirm a bearish stance, with the stock trading below all key averages. Other indicators such as the KST (Know Sure Thing) show mild bullishness weekly but mildly bearish monthly, while Dow Theory assessments align with a mildly bearish view. The On-Balance Volume (OBV) indicator is mildly bearish weekly but mildly bullish monthly, indicating mixed volume trends.
Considering Windlas Biotech Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Comparative Performance and Sector Positioning
Windlas Biotech’s performance over the past year contrasts sharply with the broader market and its sector. While the Sensex has recorded a modest gain of 0.99% over the same period, Windlas Biotech’s stock has declined by over 20%. The company’s small-cap status and its Mojo Score of 34.0, with a current Mojo Grade of Sell (downgraded from Hold on 4 Feb 2026), reflect the cautious stance adopted by market analysts. This downgrade aligns with the stock’s recent price weakness and financial metrics.
The Pharmaceuticals & Biotechnology sector itself has faced headwinds, with the Sensex trading below key moving averages and showing signs of bearish momentum. Windlas Biotech’s underperformance relative to its sector peers is notable, given its premium valuation multiples and subdued profit growth.
Summary of Key Metrics
To summarise, Windlas Biotech Ltd’s stock has declined to Rs.699.35, its lowest level in 52 weeks, amid a combination of subdued quarterly earnings, modest profit growth, and broader market weakness. The stock’s technical indicators predominantly signal bearish trends, and its valuation metrics suggest a premium relative to peers despite recent underperformance. The company’s low leverage and fair ROE provide some stability, but the stock’s recent trajectory reflects ongoing challenges in delivering shareholder returns in line with market expectations.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
